Clinical trials: Withdrawal
Colonic Neoplasms, Adenomas Serrated
Detection in Tandem Endocuff Cap Trial
A randomised back to back study comparing cap and Endocuff to detect adenomas during colonoscopy
- Conditions
- Colonic Neoplasms, Adenomas Serrated, Colo-rectal Cancer, Colon Adenoma
- Trial name
- DETECT (NCT03254498)
- Testing
- Endocuff, cap assisted colonoscopy (CAC)
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- London North West Healthcare NHS Trust
Substance Withdrawal Syndrome
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain…
- Trial name
- NCT02643355
- Testing
- Olanzapine, Clonidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Substance Withdrawal Syndrome
EA for PAAS: A pRCT
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in East and South-East Asia.
- Trial name
- NCT04917185
- Testing
- Electro-Acupuncture
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Thyroid Cancer, Metastases
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Metastases of thyroid cancer with iodine uptake are treated with repeated activity of I-131 administered after thyroid hormone withdrawal.
- Trial name
- DOSIMETA (NCT01403324)
- Testing
- TSH stimulation
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Painful Diabetic Neuropathy
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful…
- Trial name
- NCT00546351
- Testing
- Lacosamide
- Where
- 101 sites in Austria, Belgium and 13 more
- Volunteers
- 621 people
- Sponsor
- UCB Pharma
Liver Transplant
Liver Transplantation With Tregs at MGH
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
- Trial name
- LITTMUS-MGH (NCT03577431)
- Testing
- arTreg-CSB, leukapheresis, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
- Trial name
- EXPAND (NCT04666610)
- Testing
- Brivaracetam
- Where
- 35 sites in United States, Georgia and 5 more
- Volunteers
- 154 people
- Sponsor
- UCB Biopharma SRL
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Social Anxiety Disorder
Waitlist-Control Trial of Smartphone (App-based) CBT for Social Anxiety Disorder (SAD), Withdrawn
The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for social anxiety disorder (SAD).
- Trial name
- NCT04622930
- Testing
- Smartphone-delivered CBT for SAD
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Hepatitis, Autoimmune
CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS
Autoimmune hepatitis is an autoimmune chronic liver disease whose treatment includes the use of immunosuppressive drugs, particularly azathioprine, and corticosteroids. When properly treated, patients have a good survival.
- Trial name
- NCT01980745
- Testing
- Chloroquine diphosphate 250mg
- Where
- Brazil
- Volunteers
- 61 people
- Sponsor
- University of Sao Paulo General Hospital
Safety and Pharmacokinetics of Intravenous Baclofen
Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers
The objective of this study is to determine safety and characterize pharmacokinetics of higher doses of intravenous baclofen in healthy subjects.
- Trial name
- NCT01931319
- Testing
- Intravenous baclofen
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Premalignant Conditions, Malignant Lesions
To Evaluate the Best Metric for Inspection Time During a Diagnostic and/or Surveillance Upper Gastrointestinal Endoscopy (Age ≥ 18 Years, Informed Consent), Between Total Inspection Time Versus Withdrawal Time, for the Identification of Malignant Lesions
Gastric cancer is the fifth cause of cancer-related mortality worldwide. Gastric carcinogenesis involves the progression from premalignant conditions such as atrophic gastritis and intestinal metaplasia to premalignant lesions…
- Conditions
- Premalignant Conditions, Malignant Lesions, Gastric, Esophageal
- Trial name
- NCT06696209
- Testing
- Analysis of the withdrawal time of the Upper Gastrointestinal Endoscopy, Analysis of the total time of the Upper Gastrointestinal Endoscopy, Upper gastrointestinal endoscopy: Common Practices
- Where
- Portugal
- Volunteers
- 1,290 people, healthy volunteers welcome
- Sponsor
- Portuguese Oncology Institute, Coimbra
Palliative Care Nursing
Withdrawal of Artificial Nutrition at the End of Life (PERCEPAL)
Withdrawing artificial nutrition in palliative care is an issue that often leads to ethical dilemmas among health care providers, despite clinical guidelines.
- Trial name
- PERCEPAL (NCT02900573)
- Where
- France
- Volunteers
- 289 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Opioid-Related Disorders, Substance-Related Disorders
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and…
- Trial name
- NCT00000354
- Testing
- Lofexidine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorders, Cannabis Use
Cannabis and Opioid Use Disorder, Study 2
This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks.
- Trial name
- NCT07661446
- Testing
- Inhaled Cannabis, Intranasal Opioid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kentucky
Infertile High-risk Patients With Polycystic Ovaries
GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulation
To test whether GnRHa withheld 2-3 days before ovulation trigger reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovaries (PCOs) who have been treated with…
- Trial name
- NCT01634724
- Testing
- a drug withdrawal during the long protocol
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanjing University
Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
- Trial name
- NCT07227818
- Testing
- NBI-1117568
- Where
- 25 sites in United States, Puerto Rico and 1 more
- Volunteers
- 560 people
- Sponsor
- Neurocrine Biosciences
Autism Spectrum Disorders
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders
- Trial name
- NCT01288716
- Testing
- Arbaclofen
- Where
- 24 sites in United States
- Volunteers
- 150 people
- Sponsor
- Seaside Therapeutics, Inc.
Immunosuppressive Agents, Kidney Failure, Chronic
MMF and Calcineurin Inhibitor Withdrawal in CAN
Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in patients with histologically proven chronic allograft nephropathy Indication: change in immunosuppressive treatment of chronic allograft…
- Conditions
- Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Transplantation
- Trial name
- NCT00204230
- Testing
- mycophenolate mofetil (drug)
- Volunteers
- 86 people
- Sponsor
- University Hospital Muenster
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.